Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis (SIX:OCS) announced a notification dated November 18, 2025 reporting a purchase of ordinary shares by a member of the company's Board of Directors.
The notice references an attachment named notification-of-managers-transaction-lionel-carnot-november-2025, indicating the transaction involves director Lionel Carnot.
Oculis (Nasdaq: OCS) announced positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis, to be presented at ECTRIMS 2025 on September 24, 2025, 08:30 CET by Céline Louapre, M.D., Ph.D.
Topline findings reported a clinically meaningful improvement of 18 letters at 3 months, preservation of retinal ganglion cells, and a favorable safety profile. Management said the data support Privosegtor’s neuroprotective potential and plans to advance the candidate into further studies, including a program targeting MS relapses.
Oculis (Nasdaq: OCS) reported Q3 2025 results and outlined clinical and financing milestones. The company held $182.2M in cash, cash equivalents and short-term investments as of Sept 30, 2025 and completed a subsequent $110M financing that management says brings cash close to $300M, extending runway into 2029.
Key program updates: Privosegtor enters the PIONEER pivotal program (three trials: PIONEER-1 Q4 2025, PIONEER-2 H1 2026, PIONEER-3 mid-2026) for AON and NAION; OCS-01 DIAMOND Phase 3 trials are fully enrolled (>800 patients) with topline readouts expected Q2 2026 and NDA planned 2H 2026; Licaminlimab registrational genotype-based DED trial expected to start Q4 2025.
Oculis (Nasdaq: OCS) announced management participation in multiple investor conferences in November 2025, including Guggenheim (Nov 10-12), Stifel (Nov 11-13), LifeSci Capital & Sofinnova (Nov 17) and ICR Healthcare (Nov 17).
Key program items: Privosegtor advanced into registrational trials for acute optic neuritis and NAION after a positive FDA meeting; OCS-01 topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab PREDICT-1 registrational trial in DED anticipated soon as a genotype-based program. CEO Riad Sherif will give fireside chats on Nov 11 (2:30 pm ET) and Nov 12 (2:00 pm ET); management will be available for one-on-one meetings and webcasts will be posted to the Events & Presentation page.
Oculis (Nasdaq: OCS) and EURETINA awarded the Ramin Tadayoni Award 2025 to Dr. Prithvi Ramtohul for retina research.
The award, established in 2024 to honor Professor Ramin Tadayoni, supports postgraduate retinal research and recognizes Dr. Ramtohul's work on retinal imaging, including studies of retinal ganglion cell plasticity and multimodal imaging findings such as BALAD and ASHH. Oculis reiterated its collaboration with EURETINA and commitment to advancing retinal science through this annual prize.
Oculis (Nasdaq: OCS) priced an offering of 5,432,098 ordinary shares at $20.25 per share for aggregate gross proceeds of $110 million, and granted underwriters a 30-day option to buy up to 703,703 additional shares. The Offerings split into an underwritten offering of 4,691,358 shares and a registered direct offering of 740,740 shares, expected to close on or about November 3, 2025.
Of the shares, 2,635,801 are new issue from the company’s capital band and 3,500,000 are treasury shares; issuance will raise authorized registered shares to 57,169,475. Net proceeds are intended to accelerate development of Privosegtor for acute optic neuritis and NAION, and for working capital and general corporate purposes.
Oculis (NYSE:OCS) disclosed two notifications dated Oct 14, 2025 showing a director exercised vested stock options and then sold the resulting ordinary shares.
The filings indicate the transactions were executed under a 10b5-1 trading plan in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934. Attachments reference notifications for C. Ackermann covering the option exercise and subsequent share sale.
Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando, Oct 16–20, 2025.
Key updates include: Privosegtor advancing into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy after a positive meeting with the FDA; OCS-01 (DIAMOND Phase 3) with expected topline readouts in Q2 2026; and the planned PREDICT-1 registrational trial of Licaminlimab using a genotype-based approach anticipated to start in Q4 2025. CEO Riad Sherif will present at Eyecelerator on Oct 16, 2025; Oculis will also participate in Innovate Retina, SAIVO and COPhy events and staff booth 1353 during AAO.
Oculis (OCS) announced a notification of a manager's transaction dated October 8, 2025. The disclosure states that restricted stock units (RSUs) previously granted to director Riad Sherif have vested and been settled in October 2025. The notice includes an attachment with the formal managers' transaction notification.
Oculis (Nasdaq: OCS) announced a positive meeting with the FDA and is launching the PIONEER program to advance Privosegtor into registrational trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company plans three pivotal studies: PIONEER-1 (Q4 2025), PIONEER-2 (1H 2026), and PIONEER-3 (mid-2026). Primary endpoint: low-contrast visual acuity (LCVA) at 3 months, with dosing/enrollment mirroring the positive Phase 2 ACUITY trial. Oculis reported preliminary cash, cash equivalents and short-term investments of ~$182 million, with runway expected into 2H 2027. Full Q3 2025 results are planned for November 10, 2025.